We would like to announce that Dr. Anna Tinker will be stepping down from her role as GCI Clinical Trials Group Chair. The aim of the GCI Clinical Trials Group is to facilitate the translation of pre-clinical/laboratory research findings to impact patient care through the conduct of relevant clinical trials. The group’s focus is to support interventional studies including various therapeutic strategies such as surgery, chemotherapy, radiation therapy, physical therapy, nutrition, and/or counseling. They also focus on supporting investigators on integrating quality of life measures in clinical trials.
Dr. Tinker has been an invaluable member and leader of the GCI Clinical Trials Group in supporting a local team of investigators and advancing research opportunities for women affected by gynecologic cancer in BC. We want to express our gratitude for the outstanding leadership, dedication, and hard work that Dr. Tinker has demonstrated throughout her tenure.
As Dr. Tinker steps down, we are pleased to welcome Dr. Yvette Drew, who has been appointed as the new GCI Clinical Trials Group Chair. Dr. Drew brings extensive experience in cancer interventional clinical trials and a deep commitment to developing new clinical trial-focused strategies. We are confident that Dr. Drew will provide strong leadership to the group and continue to push us forward in our mission to advance gynecologic cancer clinical research.
Dr. Drew, our new GCI Clinical Trials Group Chair, has a joint faculty appointment at the rank of Associate Professor with OBGYN and the Department of Medicine, Division of Medical Oncology at UBC. Her research interests include targeting DNA repair pathways to treat gynecological cancers and PARP inhibitor resistance.
We asked Dr. Drew what she envisions for the future of the CTG. Here’s what she said:
“I am grateful for this opportunity to chair the group and huge thanks to my predecessor Dr Anna Tinker for all her hard work. I hope that in this position I can strengthen the existing group, bring in new members with additional areas of expertise and work towards translating more of the amazing Team Science that exists within BC into clinical trials that deliver improved patient care and outcomes.”
The GCI looks forward to working with Dr. Drew and supporting her vision for the future of our group. Please join us in welcoming Dr. Drew to the role and wishing her all the best in this new chapter.